The activation of PI3K/AKT and MAPK signaling is associated with the proliferation of blasts and chemoresistance in AML [35,36]; inhibition of this signaling leads to apoptosis and chemosensitivity, suggesting that these pathways could be therapeutic targets for the treatment of AML. Here, AKT1 is linked to acute myeloid leukemia.